Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Disease Types: Cholangiocarcinoma

Available at: Roanoke

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

For More Information:

https://clinicaltrials.gov/study/NCT05727176?term=Futibatinib%2020%20mg%20and%2016%20mg%20in%20Patients%20with%20Advanced%20Cholangiocarcinoma%20with%20FGFR2%20Fusions%20or%20Rearrangements&rank=1